Characteristic And Novel Therapeutic Strategies Of Nasopharyngeal Carcinoma With Synchronous Metastasis

References

• Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30(2):114–119.21272443
   PubMedGoogle Scholar
• Sun Y, Li W-F, Chen N-Y, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–1520. doi:10.1016/S1470-2045(16)30410-727686945
   PubMed Web of Science ®Google Scholar
• Liu GY, Lv X, Wu YS, et al. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. Cancer Commun (Lond). 2018;38(1):21. doi:10.1186/s40880-018-0283-229764487
   PubMedGoogle Scholar
• Liao J-F, Zhang Q, Du X-J, et al. Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis. Cancer Commun. 2019;39:1. doi:10.1186/s40880-019-0380-x
   Web of Science ®Google Scholar
• The 150 most important questions in cancer research and clinical oncology series: questions 6–14: edited by Chinese Journal of Cancer. Chin J Cancer. 2017;36(1):33. doi:10.1186/s40880-017-0200-028347321
   PubMedGoogle Scholar
• Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23(2):261–270. doi:10.1016/0360-3016(92)90740-91587745
   PubMed Web of Science ®Google Scholar
• Li AC, Xiao WW, Shen GZ, et al. Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: long-term results and benefits of chemotherapy. Oncotarget. 2015;6(27):24511–24521. doi:10.18632/oncotarget.431226087194
   PubMedGoogle Scholar
• Loong HH, Ma BB, Chan AT. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. Hematol Oncol Clin North Am. 2008;22(6):1267–1278. doi:10.1016/j.hoc.2008.08.01219010273
   PubMed Web of Science ®Google Scholar
• Liu JC, Bhayani M, Kuchta K, Galloway T, Fundakowski C. Patterns of distant metastasis in head and neck cancer at presentation: implications for initial evaluation. Oral Oncol. 2019;88:131–136. doi:10.1016/j.oraloncology.2018.11.02330616783
   PubMed Web of Science ®Google Scholar
• Tang LQ, Chen QY, Fan W, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2013;31(23):2861–2869. doi:10.1200/JCO.2012.46.081623857969
   PubMed Web of Science ®Google Scholar
• Woloschak GE, Zeng L, Tian Y-M, et al. Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis: therapeutic approaches and prognostic factors. PLoS One. 2014;9(9):e108070.25247415
   PubMed Web of Science ®Google Scholar
• Zou X, You R, Liu H, et al. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur J Cancer. 2017;77:117–126. doi:10.1016/j.ejca.2017.02.02928391025
   PubMed Web of Science ®Google Scholar
• Zhao CL, Qian GQ, Chen XY, Chen C. Retrograde analysis of clinical characteristics of bone metastasis in 1,031 cases of preliminarily diagnosed nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2014;15(8):3785–3788. doi:10.7314/apjcp.2014.15.8.378524870794
   PubMedGoogle Scholar
• Jiang R, You R, Pei XQ, et al. Development of a ten-signature classifier using a support vector machine integrated approach to subdivide the M1 stage into M1a and M1b stages of nasopharyngeal carcinoma with synchronous metastases to better predict patients’ survival. Oncotarget. 2016;7(3):3645–3657. doi:10.18632/oncotarget.643626636646
   PubMedGoogle Scholar
• Pan -C-C, Lu JIN, Yu J-R, et al. Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: A study of 1027 cases and review of the literature. Exp Ther Med. 2012;4(2):334–338. doi:10.3892/etm.2012.58423139721
   PubMed Web of Science ®Google Scholar
• Shen L-J, Wang S-Y, Xie G-F, et al. Subdivision of M category for nasopharyngeal carcinoma with synchronous metastasis: time to expand the M categorization system. Chin J Cancer. 2015;34:3. doi:10.1186/s40880-015-0031-9
   PubMedGoogle Scholar
• Shen L, Dong J, Li S, et al. M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma. Oncologist. 2015;20(3):291–298. doi:10.1634/theoncologist.2014-020625660157
   PubMed Web of Science ®Google Scholar
• Sun XS, Liang YJ, Liu SL, et al. Subdivision of nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis for prediction of survival and treatment guidance. Cancer Res Treat. 2019. doi:10.4143/crt.2018.652
   Web of Science ®Google Scholar
• Mlecnik B, Bindea G, Kirilovsky A, et al. The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8(327):327ra326. doi:10.1126/scitranslmed.aaf0746
   Web of Science ®Google Scholar
• Ono T, Azuma K, Kawahara A, et al. Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment. Head Neck. 2018;40(9):2007–2019. doi:10.1002/hed.2518929756253
   PubMed Web of Science ®Google Scholar
• Li YY, Chung GTY, Lui VWY, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat Commun. 2017;8:14121.28098136
   PubMed Web of Science ®Google Scholar
• Lin DC, Meng X, Hazawa M, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014;46(8):866–871. doi:10.1038/ng.300624952746
   PubMed Web of Science ®Google Scholar
• Zheng H, Dai W, Cheung AKL, et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci. 2016;113(40):11283–11288. doi:10.1073/pnas.160760611327647909
   PubMed Web of Science ®Google Scholar
• Hu S-x, He X-h, Dong M, et al. Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis. Med Oncol. 2015;32(9). doi:10.1007/s12032-015-0663-2
   Web of Science ®Google Scholar
• Tian YH, Zou WH, Xiao WW, et al. Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: A subset with better overall survival. Head Neck. 2016;38(8):1152–1157. doi:10.1002/hed.2434527220062
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388(10054):1883–1892. doi:10.1016/S0140-6736(16)31388-527567279
   PubMed Web of Science ®Google Scholar
• Shuang H, Feng J, Caineng C, et al. The value of radical radiotherapy in the primary tumor of newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients. Clin Transl Oncol. 2018;21(2):213–219. doi:10.1007/s12094-018-1911-729943267
   PubMed Web of Science ®Google Scholar
• Jin Y, Cai X-Y, Shi Y-X, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012;138(10):1717–1725. doi:10.1007/s00432-012-1219-x22684794
   PubMed Web of Science ®Google Scholar
• Chen M-Y, Jiang R, Guo L, et al. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis. Chin J Cancer. 2013;32(11):604–613. doi:10.5732/cjc.013.1014824206918
   PubMedGoogle Scholar
• Leong SS, Wee J, Rajan S, et al. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer. 2008;113(6):1332–1337. doi:10.1002/cncr.2368718615622
   PubMed Web of Science ®Google Scholar
• Dugan M, Choy D, Ngai A, et al. Multicenter phase II trial of mitoxantrone in patients with advanced nasopharyngeal carcinoma in Southeast Asia: an Asian-Oceanian Clinical Oncology Association Group study. J Clin Oncol. 1993;11(1):70–76. doi:10.1200/JCO.1993.11.1.708418245
   PubMed Web of Science ®Google Scholar
• Ngeow J, Lim WT, Leong SS, et al. Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann Oncol. 2010;22(3):718–722. doi:10.1093/annonc/mdq42520716628
   PubMed Web of Science ®Google Scholar
• Chua D, Wei WI, Sham JST, Au GKH. Capecitabine Monotherapy for Recurrent and Metastatic Nasopharyngeal Cancer. Jpn J Clin Oncol. 2008;38(4):244–249. doi:10.1093/jjco/hyn02218407933
   PubMed Web of Science ®Google Scholar
• Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol. 2002;13(1):150–156. doi:10.1093/annonc/mdf00211865813
   PubMed Web of Science ®Google Scholar
• Chen C, Wang F-h, Wang Z-q, et al. Salvage gemcitabine–vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol. 2012;48(11):1146–1151. doi:10.1016/j.oraloncology.2012.05.02122748450
   PubMed Web of Science ®Google Scholar
• Ma BB, Poon TC, To KF, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma–a prospective study. Head Neck. 2003;25(10):864–872. doi:10.1002/hed.1030712966511
   PubMed Web of Science ®Google Scholar
• Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol. 2005;23(27):6771–6790. doi:10.1200/JCO.2005.08.03616170185
   PubMed Web of Science ®Google Scholar
• Chua DT, Wei WI, Wong MP, Sham JS, Nicholls J, Au GK. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck. 2008;30(7):863–867. doi:10.1002/hed.2079218213730
   PubMed Web of Science ®Google Scholar
• You B, Le Tourneau C, Chen EX, et al. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. Am J Clin Oncol. 2012;35(3):255–260. doi:10.1097/COC.0b013e31820dbdcc21358293
   PubMed Web of Science ®Google Scholar
• Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005;23(15):3568–3576. doi:10.1200/JCO.2005.02.14715809453
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967–974. doi:10.1038/nature0448316355214
   PubMed Web of Science ®Google Scholar
• Chan SL, Ma BB. Novel systemic therapeutic for nasopharyngeal carcinoma. Expert Opin Ther Targets. 2012;16 Suppl 1:S63–S68. doi:10.1517/14728222.2011.63564622313344
   PubMed Web of Science ®Google Scholar
• Almobarak AA, Jebreel AB, Abu-Zaid A. Molecular targeted therapy in the management of recurrent and metastatic nasopharyngeal carcinoma: a comprehensive literature review. Cureus. 2019;11(3):e4210. doi:10.7759/cureus.388231114729
   PubMed Web of Science ®Google Scholar
• Hsu C, Lee SH, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35(36):4050–4056. doi:10.1200/JCO.2017.73.367528837405
   PubMed Web of Science ®Google Scholar
• Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic Phase 2 consortium (NCI-9742). J Clin Oncol. 2018;36(14):1412–1418. doi:10.1200/JCO.2017.77.038829584545
   PubMed Web of Science ®Google Scholar
• Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19(10):1338–1350. doi:10.1016/S1470-2045(18)30495-930213452
   PubMed Web of Science ®Google Scholar
• Hu J, Kong L, Gao J, Hu W, Guan X, Lu JJ. Use of radiation therapy in metastatic nasopharyngeal cancer improves survival: a SEER analysis. Sci Rep. 2017;7:1.28127051
   PubMed Web of Science ®Google Scholar
• Rusthoven CG, Lanning RM, Jones BL, et al. Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol. 2017;124(1):139–146. doi:10.1016/j.radonc.2017.03.01928433411
   PubMed Web of Science ®Google Scholar
• Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011;8(6):369–377. doi:10.1038/nrclinonc.2011.6421522121
   PubMed Web of Science ®Google Scholar
• Kaifi JT, Kunkel M, Dicker DT, et al. Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver. Cancer Biol Ther. 2015;16(5):690–698. doi:10.1080/15384047.2015.102650825785486
   PubMed Web of Science ®Google Scholar
• Kim M-Y, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315–1326. doi:10.1016/j.cell.2009.11.02520064377
   PubMed Web of Science ®Google Scholar
• Chen Z, Xu L, Xu X, Yuan C. The clinical value of detecting circulating tumour cells in the peripheral blood of nasopharyngeal carcinoma patients. Oncol Lett. 2018;5:6283–6290.
   Google Scholar
• Peng L, Liu JQ, Xu C, et al. The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma. Radiat Oncol. 2019;14(1):9. doi:10.1186/s13014-019-1213-430654815
   PubMedGoogle Scholar
• Yin Z, Zhang X, Wang Y, Wang P, Yuan Z. The combination of systemic therapy and locoregional radiotherapy prolongs survival in newly diagnosed metastatic nasopharyngeal carcinoma patients. Onco Targets Ther. 2017;10:5677–5683. doi:10.2147/OTT.S15003529225474
   PubMed Web of Science ®Google Scholar
• Verma V, Allen PK, Simone CB 2nd, Gay HA, Lin SH. Addition of definitive radiotherapy to chemotherapy in patients with newly diagnosed metastatic nasopharyngeal cancer. J Natl Compr Canc Netw. 2017;15(11):1383–1391. doi:10.6004/jnccn.2017.700129118230
   PubMed Web of Science ®Google Scholar
• Sun XS, Liu LT, Liu SL, et al. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy. BMC Cancer. 2019;19(1):92. doi:10.1186/s12885-019-5281-530665378
   PubMed Web of Science ®Google Scholar
• Hsieh JC-H, Du T, Xiao J, Qiu Z, Wu K. The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. PLoS One. 2019;14(7):e0219611.31291379
   PubMed Web of Science ®Google Scholar
• Lee FK-h, Yip CW-y, Cheung FC-h, Leung AK-c, Chau RM-c, Ngan RK-c. Dosimetric difference amongst 3 techniques: tomoTherapy, sliding-window intensity-modulated radiotherapy (IMRT), and RapidArc radiotherapy in the treatment of late-stage nasopharyngeal carcinoma (NPC). Med Dosim. 2014;39(1):44–49. doi:10.1016/j.meddos.2013.09.00424321222
   PubMed Web of Science ®Google Scholar
• Lee T-F, Fang F-M, Chao P-J, Su TJ, Wang LK, Leung SW. Dosimetric comparisons of helical tomotherapy and step-and-shoot intensity-modulated radiotherapy in nasopharyngeal carcinoma. Radiother Oncol. 2008;89(1):89–96. doi:10.1016/j.radonc.2008.05.01018524401
   PubMed Web of Science ®Google Scholar
• Leung SW, Lee TF. Treatment of nasopharyngeal carcinoma by tomotherapy: five-year experience. Radiat Oncol. 2013;8:107. doi:10.1186/1748-717X-8-10723634757
   PubMed Web of Science ®Google Scholar
• Holliday EB, Frank SJ. Proton therapy for nasopharyngeal carcinoma. Chin Clin Oncol. 2016;5(2):25. doi:10.21037/cco.2016.03.0527121885
   PubMedGoogle Scholar
• Hu J, Bao C, Gao J, et al. Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: initial results. Cancer. 2018;124(11):2427–2437. doi:10.1002/cncr.3131829579324
   PubMed Web of Science ®Google Scholar
• Lin S, Tham IWK, Pan J, Han L, Chen Q, Lu JJ. Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancer. Am J Clin Oncol. 2012;35(5):474–479. doi:10.1097/COC.0b013e31821a945221577086
   PubMed Web of Science ®Google Scholar
• Lo SS, Fakiris AJ, Teh BS, et al. Stereotactic body radiation therapy for oligometastases. Expert Rev Anticancer Ther. 2009;9(5):621–635. doi:10.1586/era.09.1519445579
   PubMed Web of Science ®Google Scholar
• Baliga S, Kabarriti R, Ohri N, et al. Stereotactic body radiotherapy for recurrent head and neck cancer: a critical review. Head Neck. 2017;39(3):595–601. doi:10.1002/hed.2463327997054
   PubMed Web of Science ®Google Scholar
• Ang KK, Byers RM, Peters LJ, et al. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results. Arch Otolaryngol Head Neck Surg. 1990;116(2):169–172. doi:10.1001/archotol.1990.018700200450122297407
   PubMedGoogle Scholar
• Wu SX, Chua DT, Deng ML, et al. Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;69(3):761–769. doi:10.1016/j.ijrobp.2007.03.03717601682
   PubMedGoogle Scholar
• Ma J, Wen ZS, Lin P, Wang X, Xie FY. The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases. Chin J Cancer. 2010;29(9):787–795.20800020
   PubMedGoogle Scholar
• Pan C-c, Wu P-h, Yu J-r, et al. Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation. Eur J Radiol. 2012;81(4):e473–e477. doi:10.1016/j.ejrad.2011.05.03721700408
   PubMed Web of Science ®Google Scholar
• Huang J, Li Q, Zheng Y, et al. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature. BMC Cancer. 2014;14:818. doi:10.1186/1471-2407-14-81825376591
   PubMed Web of Science ®Google Scholar
• Pan C, Wu P, Yu J, et al. CT-guided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma. Int J Hyperthermia. 2011;27(6):549–554. doi:10.3109/02656736.2011.59301921846191
   PubMed Web of Science ®Google Scholar
• Howell DD, James JL, Hartsell WF, et al. Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient. Cancer. 2013;119(4):888–896. doi:10.1002/cncr.2761623165743
   PubMed Web of Science ®Google Scholar
• Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25(11):1423–1436. doi:10.1200/JCO.2006.09.528117416863
   PubMed Web of Science ®Google Scholar
• Rich SE, Chow R, Raman S, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018;126(3):547–557. doi:10.1016/j.radonc.2018.01.00329397209
   PubMed Web of Science ®Google Scholar
• Lu T, Guo Q, Cui X, et al. Prognostic evaluation of nasopharyngeal carcinoma with bone-only metastasis after therapy. Yonsei Med J. 2016;57(4):840–845. doi:10.3349/ymj.2016.57.4.84027189275
   PubMed Web of Science ®Google Scholar
• Liang YJ, Sun XS, Yang ZC, et al. Effect of local treatment for metastasis and its sequence with chemotherapy on prognosis of post-treatment metastatic nasopharyngeal carcinoma patients. Oral Oncol. 2019;92:40–45. doi:10.1016/j.oraloncology.2019.03.01531010621
   PubMed Web of Science ®Google Scholar
• Kobiela J, Spychalski P, Marvaso G, et al. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review. Crit Rev Oncol Hematol. 2018;129:91–101. doi:10.1016/j.critrevonc.2018.06.00530097241
   PubMed Web of Science ®Google Scholar